how does tirzepatide Putative mechanism(s) of action of in cardiomyocytes Tirzepatide for Diabetes and Weight

the 3-mg dose is intended for treatment initiation and is not effective for glycemic control After 30 days on 3 mg/day: Increase to 7 mg orally once daily After 30 days on 7 mg/day: May increase dose to 14 mg orally once daily if additional glycemic control needed Note: Taking two 7-mg tablets to achieve 14 mg dose is not recommended Switching between Ozempic (SC) and Rybelsus (oral) Taking 14 mg/day orally: Transition to 0.5 mg SC once a week on the day after last oral dose Taking 0.5 mg/week SC: Transition to 7 mg or 14 mg oral starting up to 7 days after last SC injection There is no equivalent oral dose for the 1-mg SC dose Weight Management Wegovy only Indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 (obesity) or above, or 27 kg/m2 (overweight) or above in the presence of at least 1 weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia) Initiate with low dose and gradually escalate to maintenance dose of 2.4 mg/week SC to minimize gastrointestinal (GI) adverse reactions If unable to tolerate a dose during escalation, consider delaying dose escalation for 4 weeks If unable to tolerate maintenance dose of 2.4 mg once-weekly, may temporarily decrease to 1.7 mg once weekly, for a maximum of 4 weeks

At the end of AID use, laboratory testing and anthropometric measurements were performed

Sarre S, Mttnen L, Tammela TL, Auvinen A, Murtola TJ

If reconstituted, keep refrigerated at 36F46F for optimal stability

Amount paid never expires